Mesoblast Stock News

Mesoblast limited (ASX:MSB) and St Barbara Ltd (ASX:SBM) shares were among the best perfomers on the ASX 200 last week…

Mesoblast Earnings, Revenue Beat in Q2

Mesoblast press release (MEOBF): Q2 GAAP EPS of -$4.00.Revenue of $2.38M (+6.3% Y/Y).

Mesoblast Prepares for Resubmission of Biologics License Application Mesoblast Prepares for Resubmission of Biologics License Application

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation

NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from an interim analysis of the first patient cohort in the randomized, controlled study of remestemcel-L by direct endoscopic delivery to areas of inflammation in patients with medically refractory ulcerative colitis or Crohn''s colitis. A single local delivery of remestemcel-L by colonoscopy resulted in rapid mucosal healing and disease remission in these refractory patients at high risk of progression to surgery. The results of the first cohort of patients were presented at the 17 th Congress of European Crohn''s and Colitis Organisation (ECCO), February 16-19, by the trial''s lead investigator Dr. Amy L. Lightner, Associate Professor of Surgery in the Department of Colon and Rectal Surgery at Cleveland Clinic and were published in the Journal of Crohn''s and Colitis. 1,2 "Mesenchymal stromal cells (remestemcel-L) offer a safe therapeutic for the treatment of medically refractory Ulcerative Colitis and Crohn''s colitis," said Dr.

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in E

Mesoblast Limited (NASDAQ: MESO) announced 36-month follow-up results from the 400-subject Phase 3 trial of its allogeneic cell therapy rexlemestrocel-L in patients with chronic low back pain (CLBP

Mesoblast (NASDAQ:MESO) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on []

Latest Business Market Insights added report on Europe Stem Cell Therapy Market research study by Market Digits offers detailed product outlook and elaborates market review till 2027. The market Study is segmented by key regions that is accelerating the marketization.

Mesoblast Limited (NASDAQ: MESO) received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients. The trial is assessing rexl

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO , ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedback from the US Food & Drug Administration''s (FDA) Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids. Mesoblast plans to conduct an additional US Phase 3 trial which may support submissions for potential approval in both the US and EU. The trial will include at least 20% of subjects from the EU to support global submission plans. Following review of the completed Phase 3 trial data, OTAT agreed with Mesoblast''s proposal for pain reduction at 12 months as the primary endpoint of the next trial, with functional improvement and reduction in opioid use as secondary endpoints. If this trial is successful and leads to EU regulatory approval, Mesoblast will be eligible to receive payments up to US$112.5 million prior to product launch in the EU, from its partner in Europe and Latin America, Grünenthal, inclusive of US$17.5 million already received, if certain clinical and regulatory milestones are satisfied and reimbursement targets are achieved.

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedback from the US Food & Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids.

Mesoblast Limited (NASDAQ:MESO) gapped up before the market opened on Wednesday . The stock had previously closed at $4.17, but opened at $4.40. Mesoblast shares last traded at $4.37, with a volume of 3,597 shares trading hands. Several research firms have recently weighed in on MESO. Zacks Investment Research cut Mesoblast from a buy rating []

In the last trading session, 1.62 million shares of the Mesoblast Limited (NASDAQ:MESO) were traded, and its beta was 3.27. Most recently the companys share price was $4.17, and it changed around -$1.59 or -27.60% from the last close, which brings the market valuation of the company to $544.81M. MESO currently trades at a discount Mesoblast Limited (NASDAQ: MESO) Shares Might Go Down -75.16% This Year Read More »